Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
59.25
+0.84 (1.44%)
Apr 24, 2025, 4:00 PM EDT - Market closed
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalties | 570.99M | 522.62M | 482.00M | 468.82M | 447.87M | 431.79M | 416.91M | 390.51M | |||||||||||||||||
| Royalties Growth | 27.49% | 21.04% | 15.61% | 20.05% | 24.24% | 36.16% | 50.98% | 65.06% | |||||||||||||||||
| Product Sales | 303.49M | 303.73M | 303.64M | 298.64M | 300.85M | 282.42M | 257.27M | 229.68M | |||||||||||||||||
| Product Sales Growth | 0.88% | 7.55% | 18.02% | 30.02% | 57.49% | 79.98% | 113.44% | 119.59% | |||||||||||||||||
| Revenues Under Collaborative Agreements | 140.84M | 121.00M | 87.67M | 95.53M | 80.53M | 66.50M | 99.47M | 84.79M | |||||||||||||||||
| Revenues Under Collaborative Agreements Growth | 74.88% | 81.95% | -11.86% | 12.67% | -25.85% | -37.60% | 9.55% | -34.97% |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of Sales | 159.42M | 169.66M | 175.06M | 185.52M | 192.36M | 182.18M | 174.68M | 158.55M | |||||||||||||||||
| Cost of Sales Growth | -17.13% | -6.87% | 0.22% | 17.01% | 38.09% | 53.39% | 94.00% | 100.40% | |||||||||||||||||
| Selling, General, and Administrative | 154.34M | 149.69M | 143.72M | 146.96M | 149.18M | 149.32M | 148.52M | 167.05M | |||||||||||||||||
| Selling, General, and Administrative Growth | 3.45% | 0.25% | -3.23% | -12.03% | 3.94% | 24.90% | 51.16% | 214.61% | |||||||||||||||||
| Research and Development | 79.05M | 79.94M | 78.81M | 77.50M | 76.36M | 77.59M | 76.98M | 72.73M | |||||||||||||||||
| Research and Development Growth | 3.52% | 3.03% | 2.38% | 6.55% | 14.65% | 43.30% | 67.60% | 88.84% | |||||||||||||||||
| Amortization | 71.05M | 71.05M | 73.63M | 73.70M | 73.77M | 60.56M | 67.42M | 60.98M | |||||||||||||||||
| Amortization Growth | -3.69% | 17.31% | 9.22% | 20.85% | 70.98% | 56.92% | 491.20% | - |
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.